Adverse events Participants (n) reported adverse events · patients with osteoarthritis
Persea gratissma + Glycine max (ASU 300 mg) showed no clear difference in adverse events Participants (n) reported adverse events compared with chondroitin sulphate (low certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
1 finding from 1 review
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rate of adverse events excluding falls (per person year) · people with Parkinson's disease
Summary of findings for cholinesterase inhibitors may leads to higher rate of adverse events excluding falls (per person year) compared with placebo (low certainty).
1 finding from 1 review
Adverse events related to the use of physical restraints · older people in general hospital settings
1 finding from 1 review
Adverse events related to the use of physical restraints · older people
1 finding from 1 review
Dropouts due to adverse events · adults (aged 18 and older) exposed to a traumatic event
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dropouts due to adverse events · adults (aged 18 and older) exposed to a traumatic event
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dropouts due to adverse events · adults (aged 18 and older) exposed to a traumatic event
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Luteinised unruptured follicle syndrome (adverse events) · subfertile women with PCOS
It is very uncertain whether chinese herbal medicine (CHM) plus follicle aspiration plus… changes luteinised unruptured follicle syndrome (adverse events) compared with follicle aspiration plus ovulation induction (very low certainty).
1 finding from 1 review
Severe adverse events leading to withdrawal of treatment · bacterial folliculitis and boils (furuncles and carbuncles)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe adverse events leading to withdrawal of treatment · bacterial folliculitis and boils (furuncles and carbuncles)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe adverse events leading to withdrawal of treatment · bacterial folliculitis and boils (furuncles and carbuncles)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events not measured · atopic eczema
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects: perioperative complications (number of events)
Minimally invasive parathyroidectomy may leads to lower total incidence of perioperative adverse events (number) compared with bilateral neck exploration (low certainty).
1 finding from 1 review
Adverse events ‐ treatment emergent · heavy menstrual bleeding
Combined oral contraceptive pill probably leads to higher adverse events ‐ Any adverse events (treatment‐emergent) compared with placebo (moderate certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · idiopathic steroid‐resistant nephrotic syndrome in children
Calcineurin inhibitor probably leads to lower adverse events: medications ceased due to adverse events compared with IV cyclophosphamide (moderate certainty).
1 finding from 1 review
Adverse events assessed in various ways, up to 24 months · patients > 12 months of age with a severe traumatic brain injury and in a coma (post‐resuscitation GOS score ≤ 8 points) with raised,…
1 finding from 1 review
All‐cause serious adverse events 60 weeks (end of study) · patients with chronic obstructive pulmonary disease
It is very uncertain whether macrolide+tetracycline changes all‐cause serious adverse events 60 weeks (end of study) compared with macrolide (very low certainty).
1 finding from 1 review
Adverse events (disease‐related: all physical symptoms); · chronic obstructive pulmonary disease (COPD) with depression
1 finding from 1 review